Pre-Emptive Skin Treatments to Prevent Skin Toxicity Caused by Anti-EGFR Antibody: The Real-World Evidence in Japan

Yamazaki, Naoya; Oomuku, Yumi; Mishiro, Izumi; Soeda, Junpei

doi:10.2217/fon-2018-0379

Cited by 2 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yamazaki et al extracted large-scale clinical data and reported that preemptive skin treatment is widely available when EGFR inhibitors are used in Japan [ 14 ]. As a result of preventing severe skin-toxicity, dermatological visits decreased.…”

Section: Discussionmentioning

confidence: 99%

“…It was assumed that branded medicines were given to patients. The skin treatment prescription content was set based on previous reports [ 14 , 16 ]. Costs were calculated according to 2020 medical fees and drug tariff in Japan [ 17 , 18 ].…”

Section: Methodsmentioning

confidence: 99%

“…Based on these results, preemptive skin treatment is recommended over reactive skin treatment [ 12 , 13 ]. It has been reported that preemptive skin treatment is widely used in real world clinical settings [ 14 ]. However, the cost-effectiveness of preventive treatment is unclear.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Kashiwa

Matsushita

2021

J Pharm Health Care Sci

View full text Add to dashboard Cite

Background Clinical management of skin-toxicity associated with the use of anti-Epidermal Growth Factor Receptor (EGFR) antibodies to treat colorectal cancer maintains quality of life of patients with colorectal cancer. Results of clinical trials have recommended the efficacy of prophylactic treatment, but the cost-effectiveness is unclear. This study examined the cost-effectiveness of preventive skin care for skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer from the perspective of the Japanese healthcare payer. Methods The data source was J-STEPP trial, which compared preemptive skin treatment with reactive treatment in third-line panitumumab therapy for KRAS wild type metastatic colorectal cancer in Japan. The costs and effectiveness of preemptive treatment was compared with reactive treatment in a 3-year time horizon using a 4-state partitioned survival analysis. The health outcome was quality-adjusted life-years (QALYs). The costs were 2020 revisions to the drug prices. The robustness of the model was verified by one-way sensitivity analysis and a probabilistic sensitivity analysis (PSA). A 2% annual discount was applied to the expenses and QALYs. Willingness-to-pay (WTP) threshold of 5 million JPY was used. Results Preemptive treatment had incremental effects of 0.0029 QALYs, incremental costs of 5300 JPY (48.6 USD), and incremental cost-effectiveness ratios (ICER) of 1,843,395 JPY (16,912 USD) per QALY. The variability of preemptive and reactive treatment costs for skin-toxicity and the disutility of skin-toxicity had a large impact on ICER. From PSA, the cost-effectiveness rate of preemptive treatment was 75.0%. Conclusions The cost to effectiveness of preemptive treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type mCRC is not high.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Kashiwa

Matsushita

2021

J Pharm Health Care Sci

View full text Add to dashboard Cite

show abstract

“…Recently, in Japan, colorectal cancer research has been conducted using claims data [ 19 – 21 ]; however, the accuracy of the algorithms used has not been reported. Outside Japan, some studies have validated algorithms to identify colorectal cancers [ 22 – 24 ].…”

Section: Introductionmentioning

confidence: 99%

Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital

Hirano

Negishi

Kuwatsuru

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background Administrative claims data are a valuable source for clinical studies; however, the use of validated algorithms to identify patients is essential to minimize bias. We evaluated the validity of diagnostic coding algorithms for identifying patients with colorectal cancer from a hospital’s administrative claims data. Methods This validation study used administrative claims data from a Japanese university hospital between April 2017 and March 2019. We developed diagnostic coding algorithms, basically based on the International Classification of Disease (ICD) 10th codes of C18–20 and Japanese disease codes, to identify patients with colorectal cancer. For random samples of patients identified using our algorithms, case ascertainment was performed using chart review as the gold standard. The positive predictive value (PPV) was calculated to evaluate the accuracy of the algorithms. Results Of 249 random samples of patients identified as having colorectal cancer by our coding algorithms, 215 were confirmed cases, yielding a PPV of 86.3% (95% confidence interval [CI], 81.5–90.1%). When the diagnostic codes were restricted to site-specific (right colon, left colon, transverse colon, or rectum) cancer codes, 94 of the 100 random samples were true cases of colorectal cancer. Consequently, the PPV increased to 94.0% (95% CI, 87.2–97.4%). Conclusion Our diagnostic coding algorithms based on ICD-10 codes and Japanese disease codes were highly accurate in detecting patients with colorectal cancer from this hospital’s claims data. The exclusive use of site-specific cancer codes further improved the PPV from 86.3 to 94.0%, suggesting their desirability in identifying these patients more precisely.

show abstract

Pre-Emptive Skin Treatments to Prevent Skin Toxicity Caused by Anti-EGFR Antibody: The Real-World Evidence in Japan

Abstract: Pre-emptive skin treatments seem to be related to reducing subsequent dermatologist visits by severe skin toxicity prevention and gained popularity in Japan.

Cited by 2 publications

References 15 publications

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan

Validation of algorithms to identify colorectal cancer patients from administrative claims data of a Japanese hospital

Contact Info

Product

Resources

About